#Cancer Treatment #Precision Medicine #SynerTri Immunotherapy

Introduction

In a significant advancement in cancer treatments, the Precision Medical Care Corporation has announced that its complex cancer immunotherapy, SynerTri Immunotherapy®, has received a domestic trademark as of April 6, 2026. Located in Chuo, Tokyo, the Precision Clinic, directed by Dr. Yuichiro Yazaki, is now positioned to deliver a cutting-edge, patient-tailored approach to cancer care.

What is SynerTri Immunotherapy®?

SynerTri Immunotherapy® represents a revolutionary approach to cancer treatment by integrating three key components: dendritic cell vaccine therapy, immune checkpoint inhibitors, and local therapy. The treatment strategy focuses on activating the immune response through three crucial mechanisms: the Switch, Release the Brake, and Accelerate.

Treatment Strategy

1. Local Therapy (such as Radiation): Cancer cells are targeted and destroyed, making the immune system aware of their presence.
2. Immune Checkpoint Inhibitors: These works by releasing the immune system from being suppressed and activating the body's natural defense mechanisms against cancer.
3. Dendritic Cell Vaccine Therapy: This final step properly signals the immune system with cancer's unique characteristics, significantly enhancing its ability to target and attack malignancies.

By systematically combining these three elements, the SynerTri Immunotherapy® aims to significantly boost the immune response against cancer.

Background of Trademark Acquisition

In the past, cancer treatment options primarily included surgery, chemotherapy, and radiation. However, the recent advancements in immunotherapy have expanded the choices available to patients. With approximately 6,500 cases analyzed, the Precision Clinic has been at the forefront since its inception in 2005 with a commitment to combining dendritic cell vaccine therapy and local therapies.

Through the accumulated data and expertise, the clinic has made strides in understanding immune mechanisms and how to elicit effective immune responses. The integration of AI technologies now enables a detailed analysis of individual patients' immune states, paving the way for personalized treatment strategies.

Academic Validation and Global Outreach

In 2024, the treatment strategy was co-authored by Dr. Yazaki and presented at the American Association for Cancer Research (AACR) Annual Meeting during poster session #3741. The findings were published in AACR's prestigious journal, Cancer Research, affirming the scientific validity of this innovative approach.

Additionally, a detailed report on a stage IV unresectable pharyngeal cancer case that achieved a complete cure through this therapy was published in the international peer-reviewed journal CUREUS. This treatment strategy is defined academically as iCCI (innovative combination cancer immunotherapy) with